Case Presentation: We present the case of a 49-year-old transgender woman (MTF) with ESRD on hemodialysis and opioid use disorder maintained on high-dose methadone (149 mg/day), who presented with hypotension and profound weakness following suspected volume loss. She was noted to be hypotensive with MAPs in the 40–50s despite 2L IV fluids and 100 mg IV hydrocortisone, necessitating vasopressor support and ICU admission. During hospitalization, she developed recurrent, unexplained hypoglycemia (nadir 35 mg/dL), persistent hyponatremia (128–132), and hyperkalemia refractory to dialysis.Initial differential diagnosis included adrenal insufficiency, sepsis, hepatic dysfunction, and dialysis-related metabolic shifts. Endocrine workup revealed preserved cortisol response on cosyntropin stimulation, ruling out primary adrenal insufficiency. However, she exhibited hyperprolactinemia and suppressed gonadotropins, consistent with central hypogonadotropic hypogonadism. Thyroid studies revealed subclinical hypothyroidism, prompting levothyroxine initiation. Brain MRI showed no mass lesion or pituitary structural abnormality. CT abdomen revealed nonspecific sigmoid colitis, and infectious workup was negative.Given persistent hypoglycemia despite standard management and absence of other etiologies, methadone-associated endocrinopathy was suspected.
Discussion: Chronic opioid therapy is well known to exert inhibitory effects on the hypothalamo–pituitary–end organ axes. Hypogonadism, hypocortisolism, and hyperprolactinemia are frequently observed in patients on long-term opioids, particularly methadone. Recent data has expanded methadone’s adverse effect profile to include a unique, dose-dependent risk of hypoglycemia—most notably at doses ≥40 mg/day. While pituitary dysfunction is increasingly recognized among opioid users, the concurrent development of hypoglycemia and hypothalamic–pituitary axis disruption remains rarely described.
Conclusions: Given the patient’s persistent hypoglycemia despite standard management and absence of other etiologies, methadone-associated endocrinopathy was suspected. Case reports suggest methadone may directly stimulate insulin secretion, leading to hyperinsulinemic, hypoketotic hypoglycemia—recognized in FDA labeling. This insulinotropic effect, combined with central pituitary dysfunction, supported the diagnosis of methadone-induced dual endocrinopathy. Management included stress-dose steroids, glucose supplementation, and dialysis. Transition to buprenorphine/naloxone was offered but declined by the patient due to past adverse effects.This case underscores the unique pathophysiologic potential of high-dose methadone to impair glucose and hormonal regulation. It highlights diagnostic delays that may occur due to symptom overlap with adrenal crisis, renal disease, or infection. Clinicians should maintain a high index of suspicion for methadone-related endocrine disorders in patients with unexplained hypoglycemia, hyponatremia, or hypotension—especially when pituitary axis involvement is suspected. Comprehensive hormonal assessment and methadone dose review are critical to prevent recurrence and reduce morbidity.